Alnylam Pharmaceuticals Inc. Q2 Earnings Summary
(RTTNews) - Below are the earnings highlights for Alnylam Pharmaceuticals Inc. (ALNY):
Earnings: -$16.889 million in Q2 vs. -$276.024 million in the same period last year. EPS: -$0.13 in Q2 vs. -$2.21 in the same period last year. Excluding items, Alnylam Pharmaceuticals Inc. reported adjusted earnings of $73.766 million or $0.56 per share for the period.
Analysts projected -$1.08 per share Revenue: $659.825 billion in Q2 vs. $318.754 billion in the same period last year.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.